DuPont Reports 4Q and Full-Year 2012 EPS of $.11 and $3.33 Ex-items

     DuPont Reports 4Q and Full-Year 2012 EPS of $.11 and $3.33 Ex-items

Expects Modest Growth in 2013 Operating Earnings

PR Newswire

WILMINGTON, Del., Jan. 22, 2013

WILMINGTON, Del., Jan. 22, 2013 /PRNewswire/ --

Fourth Quarter:

  oFourth quarter 2012 earnings per share (EPS) from continuing operations,
    excluding significant items, was $.11 versus prior year earnings of $.26.
    Reported fourth quarter 2012 EPS from continuing operations was $.02
    versus $.31 in the prior year.

  oSales of $7.3 billion equaled the prior year. Three percent higher volume
    was offset by 2 percent negative currency impact and a 1 percent reduction
    from portfolio changes.

  oSegment pre-tax operating income (PTOI) was down, primarily reflecting
    lower price and volume in Performance Chemicals. Titanium dioxide pricing
    led the decline.

Full Year:

  o2012 EPS from continuing operations, excluding significant items, was
    $3.33 versus $3.55 in 2011. Currency was a $.27 per share headwind for
    the year. Reported EPS from continuing operations was $2.61 versus $3.30
    in 2011 (see Schedule B.)

  oSales were $34.8 billion, up 3 percent with a 6 percent increase in
    developing markets.

  oSegment PTOI increased 3 percent to $5.7 billion, excluding
    Pharmaceuticals and significant items. Agriculture PTOI increased 18
    percent driven by volume and pricing growth for seed and crop protection
    businesses in North America and Latin America. Performance Chemicals PTOI
    decreased 16 percent from lower sales across the segment.

  oFree cash flow was $3.1 billion versus $3.3 billion in the prior year.
    2012 includes a $0.5 billion contribution to the principal U.S. pension
    plan and lower net income, partly offset by improved working capital
    productivity.

  oFixed cost and working capital productivity benefits were each about $400
    million, surpassing their
    $300 million targets.

  oReflecting the change in reporting for the cost of non-operating pension
    and other post-employment benefits and excluding significant items, 2012
    operating earnings were $3.77 per share. On the same basis, the 2013
    outlook for operating earnings is $3.85 to $4.05 per share, an increase of
    2 to 7 percent over the prior year.

"DuPont stands stronger today than it did a year ago. Our segments delivered
innovation, productivity and integration cost synergies. This, coupled with a
record year in new product introductions, has strengthened our market
position," said DuPont Chair and CEO Ellen Kullman. "However, weakness in
markets served by Performance Chemicals and Electronics & Communications
provided significant challenges in 2012. We've adjusted our plans to meet the
changing market environment and grow our businesses in a slow-growth world
economy."

Global Consolidated Sales - 4^th Quarter
Fourth quarter 2012 sales were $7.3 billion, flat versus the prior year.
Currency impact and portfolio changes offset 3 percent volume growth. Volume
was driven by Agriculture, with robust sales in Latin America and a strong
start to the North American selling season, and increases in Asia Pacific for
Performance Materials, Electronics & Communications and Performance
Chemicals. The table below shows fourth quarter regional sales and variances
versus fourth quarter 2011.

                        Three Months
                        Ended              Percentage Change Due to:
                        December 31, 2012
                                           Local  Currency          Portfolio/
(Dollars in billions)   $        % Change         Effect    Volume
                                           Price                    Other
U.S. & Canada           $      -         2      -         -       (2)
                        2.5
EMEA*                   1.6      (8)       (1)    (4)       (2)     (1)
Asia Pacific            1.9      -         (5)    (1)       6       -
Latin America           1.3      10        7      (4)       8       (1)
Total Consolidated      $      -         -      (2)       3       (1)
Sales                   7.3

Global Consolidated Sales - Full-Year
Full-year 2012 sales were $34.8 billion, up 3 percent versus 2011, reflecting
4 percent higher local prices, 2 percent adverse currency impact, 2 percent
lower volume, and a 3 percent net increase from portfolio changes. Local
prices increased for all segments except Electronics & Communications which
had lower pass-through of metals prices. Lower global volume principally
reflects decreases for Performance Chemicals and Electronics & Communications,
partly offset by higher Agriculture volumes. The table below shows regional
sales and variances versus 2011.

                        Year Ended         Percentage Change Due to:
                        December 31, 2012
                                           Local  Currency          Portfolio/
(Dollars in billions)   $        % Change         Effect    Volume
                                           Price                    Other
U.S. & Canada           $       8         6      -         -       2
                        14.2
EMEA*                   8.1      (1)       3      (6)       (4)     6
Asia Pacific            8.0      (4)       (1)    (1)       (5)     3
Latin America           4.5      11        9      (5)       5       2
Total Consolidated      $       3         4      (2)       (2)     3
Sales                   34.8
* Europe, Middle East & Africa

Income from Continuing Operations - 4^th Quarter
Excluding significant items, fourth quarter 2012 income from continuing
operations was $110 million versus $246 million in the prior year. The
decrease principally reflects lower income from Performance Chemicals and
Pharmaceuticals, increased spending for growth initiatives and adverse
currency impact. Reported fourth quarter 2012 income from continuing
operations was $19 million versus $293 million in the fourth quarter 2011.

Earnings Per Share - 4^th Quarter
The table below shows year-over-year earnings per share (EPS) variances for
the fourth quarter.

EPS ANALYSIS
                                                      4Q
EPS 2011                                              $.31
 Less: Significant items - (schedule B)             .05
EPS 2011 –Excluding significant items                 .26
 Local prices                                       (.01)
 Variable cost*                                     .12
 Volume                                             (.03)
 Fixed cost*                                        (.12)
 Currency                                           (.04)
 Income tax                                         .04
 Pharmaceuticals income                             (.06)
 Other**                                            (.05)
EPS 2012 – Excluding significant items              $.11
 Add: Significant items - (schedule B)              (.09)
EPS 2012                                              $.02
*Excludes volume and currency impacts
** Includes interest expense, net exchange gains/losses, and other income

Business Segment Performance - 4^th Quarter
The tables below show fourth quarter 2012 segment sales with related
variances versus the prior year and fourth quarter PTOI excluding significant
items.

SEGMENT SALES*                Three Months Ended    Percentage Change
(Dollars in billions)         December 31, 2012     Due to:
                                                    USD            Portfolio
                              $           % Change         Volume
                                                    Price          and Other
Agriculture                   $   1.5  18        7      11      -
Electronics & Communications 0.6         (1)       (3)    2       -
Industrial Biosciences        0.3         4         1      3       -
Nutrition & Health            0.9         6         3      3       -
Performance Chemicals         1.6         (15)      (7)    (8)     -
Performance Materials         1.5         (5)       (5)    3       (3)
Safety & Protection           1.0         2         (1)    3       -
* Segment sales include transfers



SEGMENT PTOI excluding Significant                          Change versus 2011
Items*
(Dollars in millions)                 4Q 2012    4Q 2011    $            %
Agriculture                           $        $  (116)  $   24    21%
                                      (92)
Electronics & Communications          24         42         (18)         -43%
Industrial Biosciences                44         34         10           29%
Nutrition & Health                    66         52         14           27%
Performance Chemicals                 200        433        (233)        -54%
Performance Materials                 254        151        103          68%
Safety & Protection                   88         94         (6)          -6%
Other                                 (71)       (74)       3            nm
                                      $   513  $   616  $  (103)    -17%
Pharmaceuticals                       9          89         (80)         -90%
Total Segment PTOI                    $   522  $   705  $  (183)    -26%
* See Schedules B and C for listing of significant items and their
impact by segment.

Business Segment Performance - Full Year
The tables below show full-year 2012 segment sales with related variances
versus the prior year, and full-year PTOI excluding significant items.

                              12 Months Ended      Percentage Change
SEGMENT SALES*                December 31, 2012    Due to:
(Dollars in billions)
                                                   USD            Portfolio
                              $          % Change         Volume
                                                   Price          and Other
Agriculture                   $  10.4  14        6      8       -
Electronics & Communications 2.7        (15)      (4)    (11)    -
Industrial Biosciences        1.2        67        (4)    8       63
Nutrition & Health            3.4        39        1      3       35
Performance Chemicals         7.2        (8)       4      (12)    -
Performance Materials         6.4        (5)       (2)    -       (3)
Safety & Protection           3.8        (3)       -      (3)     -
* Segment sales include transfers



SEGMENT PTOI excluding Significant Items*
(Dollars in millions)                                       Change versus 2011
                                   FY 2012       FY 2011    $             %
Agriculture                        $ 2,063      $  1,752  $   311    18%
Electronics & Communications       172           355        (183)         -52%
Industrial Biosciences             171           78         93            119%
Nutrition & Health                 348           170        178           105%
Performance Chemicals              1,622         1,923      (301)         -16%
Performance Materials              1,117         924        193           21%
Safety & Protection                418           500        (82)          -16%
Other                              (259)         (235)      (24)          nm
                                   $ 5,652      $  5,467  $   185    3%
Pharmaceuticals                    62            289        (227)         -79%
Total Segment PTOI                 $ 5,714      $  5,756  $          -1%
                                                            (42)
* See Schedules B and C for listing of significant items and their impact by
segment.

The following is a summary of business results for each of the company's
reportable segments in the fourth quarter (unless otherwise noted), comparing
current period with the prior year, for sales and PTOI (loss) excluding
significant items. References to selling price are on a U.S. dollar basis,
including the impact of currency.

Agriculture – Sales of $1.5 billion were up 18 percent on 11 percent higher
volume and 7 percent higher prices despite the negative impact of currency.
PTOI seasonal loss of ($92) million improved $24 million on higher volume in
Latin America and stronger than expected pricing gains, partially offset by
continued investment in commercial and R&D activities.

Full-year sales of $10.4 billion grew 14 percent on 8 percent higher volume
and 6 percent higher prices. Pioneer seed sales increased from higher global
volume and pricing gains in corn and soybeans. Crop Protection sales grew on
strong demand for insecticides and herbicides in all regions. Full-year PTOI
increased 18 percent as strong sales more than offset unfavorable currency and
higher investments in commercial and R&D activities to support growth.

Electronics & Communications – Sales of $622 million were down 1 percent, with
2 percent higher volume offset by
3 percent lower prices, primarily pass-through of lower metals prices. Volume
growth from increased demand for materials in smart phones and tablets was
partly offset by continued softness in photovoltaic materials. PTOI declined
$18 million as the prior year included OLED technology licensing income of $20
million.

Industrial Biosciences – Sales of $300 million were up 4 percent on 3 percent
higher volume and 1 percent higher prices. Volume growth reflects strong
sales of Sorona^® polymer for carpeting, and continued growth in food enzymes
in Europe. PTOI of $44 million was up $10 million on higher volume and the
benefit of synergies realized from the integration of the Danisco enzyme
business.

Nutrition & Health –  Sales of $853 million were up 6 percent on 3 percent
higher volume and 3 percent higher prices. Volume growth reflects strong
demand for probiotics, cultures and enablers. Higher local prices in all
regions were partly offset by unfavorable currency. PTOI of $66 million was
up $14 million on higher sales and the benefit of synergies realized from the
integration of the Danisco specialty food ingredients business, partly offset
by higher raw material costs.

Performance Chemicals – Sales of $1.6 billion were down 15 percent, with 8
percent lower volume and 7 percent lower prices. Lower volume resulted
primarily from weak demand for fluoropolymers in U.S. and Europe. Lower
prices reflect cyclical pressure in the titanium dioxide market. PTOI of $200
million decreased $233 million on lower sales and plant utilization in both
businesses.

Performance Materials – Sales of $1.5 billion were down 5 percent, with 5
percent lower prices and a 3 percent reduction from a portfolio change, partly
offset by 3 percent higher volume. Stable packaging markets and strong demand
in the North American automotive market were partially offset by softness in
the industrial and electronics markets and a weak Europe. PTOI of $254
million increased $103 million due to lower feedstock costs, higher volume and
mix enrichment, partly offset by unfavorable currency.

Safety & Protection – Sales of $964 million were up 2 percent on 3 percent
higher volume, partly offset by 1 percent lower prices due to unfavorable
currency. Volume increased on higher demand for Sustainable Solutions
offerings and U.S. residential and commercial construction products. PTOI of
$88 million decreased $6 million primarily due to lower plant utilization
related to softness in certain industrial markets and U.S. public sector
markets.

Additional information is available on the DuPont Investor Center website at
http://www.investors.dupont.com.

Outlook
Reflecting the change in reporting for the cost of non-operating pension and
other post-employment benefits and excluding significant items, 2012 operating
earnings were $3.77 per share. On the same basis, the 2013 outlook for
operating earnings is $3.85 to $4.05 per share, an increase of 2 to 7 percent
over the prior year. First half 2013 operating earnings are expected to
decline modestly on a year-over-year basis. Additionally, full-year 2013
sales are expected to be about $36 billion.

Use of Non-GAAP Measures
Management believes that certain non-GAAP measurements are meaningful to
investors because they provide insight with respect to ongoing operating
results of the company. Such measurements are not recognized in accordance
with generally accepted accounting principles (GAAP) and should not be viewed
as an alternative to GAAP measures of performance. Reconciliations of
non-GAAP measures to GAAP are provided in schedules C and D.

DuPont (NYSE: DD) has been bringing world-class science and engineering to the
global marketplace in the form of innovative products, materials, and services
since 1802. The company believes that by collaborating with customers,
governments, NGOs, and thought leaders we can help find solutions to such
global challenges as providing enough healthy food for people everywhere,
decreasing dependence on fossil fuels, and protecting life and the
environment. For additional information about DuPont and its commitment to
inclusive innovation, please visit http://www.dupont.com.

Forward-Looking Statements: This news release contains forward-looking
statements which may be identified by their use of words like "plans,"
"expects," "will," "believes," "intends," "estimates" or other words of
similar meaning. All statements that address expectations or projections
about the future, including statements about the company's growth strategy,
product development, regulatory approval, market position, anticipated
benefits of acquisitions, outcome of contingencies, such as litigation and
environmental matters, expenditures and financial results, are forward-looking
statements. Forward-looking statements are not guarantees of future
performance and are based on certain assumptions and expectations of future
events which may not be realized. Forward-looking statements also involve
risks and uncertainties, many of which are beyond the company's control. Some
of the important factors that could cause the company's actual results to
differ materially from those projected in any such forward-looking statements
are: fluctuations in energy and raw material prices; failure to develop and
market new products and optimally manage product life cycles; significant
litigation and environmental matters; failure to appropriately manage process
safety and product stewardship issues; changes in laws and regulations or
political conditions; global economic and capital markets conditions, such as
inflation, interest and currency exchange rates; business or supply
disruptions; security threats, such as acts of sabotage, terrorism or war,
weather events and natural disasters; inability to protect and enforce the
company's intellectual property rights; and integration of acquired businesses
and completion of divestitures of underperforming or non-strategic assets or
businesses. The company undertakes no duty to update any forward-looking
statements as a result of future developments or new information.



E. I. du Pont de Nemours and Company

Consolidated Income Statements

(Dollars in millions, except per share amounts)
SCHEDULE A
                          Three Months Ended          Year Ended
                          December 31,                December 31,
                          2012           2011         2012         2011
Net sales                 $          $        $         $   
                          7,325         7,343       34,812      33,681
Other income, net^(a)     247            338          498          742
Total                     7,572          7,681        35,310       34,423
Cost of goods sold
and other operating       5,983          5,927        25,604       24,874
charges ^(a)
Selling, general and
administrative            842            791          3,567        3,358
expenses
Research and
development expense       547            527          2,067        1,910
^(a)
Interest expense         117            116          464          447
Employee separation /
asset related             99             17           493          53
charges, net ^(a)
Total                     7,588          7,378        32,195       30,642
(Loss) income from
continuing operations     (16)           303          3,115        3,781
before income taxes
(Benefit from)
provision for income      (35)           10           622          626
taxes on continuing
operations
Income from
continuing operations     19             293          2,493        3,155
after income taxes
Net income from
discontinued              93             84           320          355
operations after
taxes
Net income               112            377          2,813        3,510
Less: Net income
attributable to           1              4            25           36
noncontrolling
interests
Net income                $        $       $        $    
attributable to           111             373        2,788       3,474
DuPont
Basic earnings per
share of common stock
^(b):
Basic earnings per
share of common stock     $         $       $       $     
from continuing           0.02          0.31        2.63        3.35
operations
Basic earnings per
share of common stock     0.10           0.09         0.34         0.38
from discontinued
operations
Basic earnings per        $         $       $       $     
share of common stock     0.12          0.40        2.98        3.73
Diluted earnings per
share of common stock
^(b):
Diluted earnings per
share of common stock     $         $       $       $     
from continuing           0.02          0.31        2.61        3.30
operations
Diluted earnings per
share of common stock     0.10           0.09         0.34         0.38
from discontinued
operations
Diluted earnings per      $         $       $       $     
share of common stock     0.12          0.40        2.95        3.68
Dividends per share       $         $       $       $     
of common stock        0.43          0.41        1.70        1.64
Average number of
shares outstanding
used in earnings per
share (EPS)
calculation:
 Basic                   933,420,000    925,588,000  933,275,000  928,417,000
 Diluted                 941,219,000    935,709,000  942,197,000  941,029,000
(a) See Schedule B for
detail of significant
items.
(b) The sum of the individual earnings
per share amounts may not equal the
total due to rounding.



E. I. du Pont de Nemours and Company

Condensed Consolidated Balance Sheets

(Dollars in millions, except per share amounts)
SCHEDULE A (continued)
                                          December 31,       December 31,
                                          2012               2011
Assets
Current assets
Cash and cash equivalents                 $      4,284  $      3,586
Marketable securities                     123                433
Accounts and notes receivable, net       5,452              6,022
Inventories                              7,422              7,195
Prepaid expenses                          204                151
Deferred income taxes                    650                671
Assets held for sale                      3,056              -
Total current assets                      21,191             18,058
Property, plant and equipment, net of
accumulated depreciation                  12,741             13,412
 (December 31, 2012 - $19,085;
December 31, 2011 - $19,349)
Goodwill                                  4,616              5,413
Other intangible assets                  5,126              5,413
Investment in affiliates                  1,163              1,117
Deferred income taxes                    3,939              4,067
Other assets                              960                1,012
Total                                     $     49,736   $     48,492
Liabilities and Equity
Current liabilities
Accounts payable                          $      4,853  $      4,816
Short-term borrowings and capital lease   1,275              817
obligations
Income taxes                             340                255
Other accrued liabilities                 5,997              5,297
Liabilities related to assets held for    1,084              -
sale
Total current liabilities                 13,549             11,185
Long-term borrowings and capital lease    10,465             11,736
obligations
Other liabilities                         14,687             15,508
Deferred income taxes                     856                1,001
Total liabilities                         39,557             39,430
Commitments and contingent liabilities
Stockholders' equity
Preferred stock                           237                237
Common stock, $0.30 par value;
1,800,000,000 shares authorized;
 Issued at December 31, 2012 -          306                304
1,020,057,000; December 31, 2011 -
1,013,164,000
Additional paid-in capital                10,632             10,107
Reinvested earnings                       14,286             13,422
Accumulated other comprehensive loss     (8,646)            (8,750)
Common stock held in treasury, at cost
(87,041,000 shares                        (6,727)            (6,727)
 at December 31, 2012 and 2011)
Total DuPont stockholders' equity         10,088             8,593
Noncontrolling interests                  91                 469
Total equity                              10,179             9,062
Total                                     $     49,736   $     48,492



E. I. du Pont de Nemours and Company

Condensed Consolidated Statement of Cash Flows

(Dollars in millions, except per share amounts)
SCHEDULE A (continued)
                                                            Year Ended
                                                            December 31,
Total Company                                               2012     2011
Cash provided by (used for) operating activities            $ 4,849  $ 5,152
Investing activities
Purchases of property, plant and equipment                  (1,793)  (1,843)
Investments in affiliates                                   (97)     (67)
Payments for businesses (net of cash acquired)              (18)     (6,459)
Net (increase) decrease in short-term financial instruments 315      2,149
Proceeds from sales of assets - net of cash sold            302      214
Other investing activities - net                            (55)     (232)
Cash provided by (used for) investing activities            (1,346)  (6,238)
Financing activities
Dividends paid to stockholders                              (1,594)  (1,533)
Net increase (decrease) in borrowings                       (793)    1,561
Repurchase of common stock                                  (400)    (672)
Proceeds from exercise of stock options                     550      952
Payments for noncontrolling interest                        (470)    -
Other financing activities - net                            10       95
Cash provided by (used for) financing activities            (2,697)  403
Effect of exchange rate changes on cash                     (13)     6
Cash classified as held for sale                            (95)     -
Increase (decrease) in cash and cash equivalents            698      (677)
Cash and cash equivalents at beginning of period            3,586    4,263
Cash and cash equivalents at end of period                  $ 4,284  $ 3,586



E. I. du Pont de Nemours and Company

Schedule of Significant Items from Continuing Operations

(Dollars in millions, except per share amounts)
SCHEDULE B
SIGNIFICANT ITEMS FROM CONTINUING
OPERATIONS
                         Pre-tax            After-tax         ($ Per Share)
                         2012     2011      2012     2011     2012    2011
1st Quarter
Customer claims charge   $       $      $       $     $       $   
^(a)                     (50)     -         (32)     -        (0.04)  -
1st Quarter - Total      $       $      $       $     $       $   
                         (50)     -         (32)     -        (0.04)  -
2nd Quarter
Customer claims charge   $ (265)  $   -   $ (169)  $   -  $       $   -
^(a)                                                          (0.18)
Litigation settlement    (137)    -         (123)    -        (0.13)  -
^(b)
Gain on the sale of
equity
    method investment    122      -         77       -        0.08    -
    ^(c)
Transition costs related
to the
    acquisition of       -        (103)     -        (81)     -       (0.08)
    Danisco^(d)
2nd Quarter - Total      $ (280)  $ (103)   $ (215)  $       $       $ (0.08)
                                                     (81)     (0.23)
3rd Quarter
Customer claims charge   $ (125)  $  (75)  $       $       $       $ (0.05)
^(a)                                        (80)     (48)     (0.09)
Restructuring charge     (152)    -         (105)    -        (0.11)  -
^(e)
Asset impairment charge  (242)    -         (157)    -        (0.17)  -
^(f)
Transition costs and
restructuring charge
    related to the
    acquisition of       -        (171)     -        (122)    -       (0.13)
    Danisco ^(g)
Charge related to
milestone payment
    for licensing        -        (50)      -        (33)     -       (0.03)
    agreement ^(h)
3rd Quarter - Total      $ (519)  $ (296)   $ (342)  $ (203)  $       $ (0.21)
                                                              (0.37)
4th Quarter
Customer claims charge   $ (135)  $ (100)   $       $       $       $ (0.07)
^(a)                                        (89)     (64)     (0.09)
Restructuring            (66)     (17)      (56)     (11)     (0.06)  (0.01)
charge/adjustments ^(i)
Asset impairment charge  (33)     -         (21)     -        (0.02)  -
^(j)
Gain on sale of business 117      -         75       -        0.08    -
^(k)
Sale of a business ^(l)  -        49        -        122      -       0.13
4th Quarter - Total      $ (117)  $  (68)  $       $  47  $       $ 0.05
                                            (91)              (0.09)
Full Year - Total ^(m)   $ (966)  $ (467)   $ (680)  $ (237)  $       $ (0.25)
                                                              (0.72)



E. I. du Pont de Nemours and Company

Schedule of Significant Items from Continuing Operations

(Dollars in millions, except per share amounts)
SCHEDULE B (continued)
SIGNIFICANT ITEMS FROM CONTINUING OPERATIONS
        Fourth quarter 2012, third quarter 2012, second quarter 2012, first
        quarter 2012, fourth quarter 2011, and third quarter 2011 included
        charges of $(135), $(125), $(265), $(50), $(100), and $(75),
        respectively, recorded in Cost of goods sold and other operating
        charges associated with the company's process to fairly resolve claims
        related to the use of Imprelis® herbicide, bringing the total charges
        to $(750) at December 31, 2012. The company will continue to evaluate
        reported claim damage as additional information becomes available. It
(a)     is reasonably possible that additional charges could result from this
        evaluation. While there is a high degree of uncertainty, total charges
        could range as high as $(900). The company has an applicable insurance
        program with a deductible equal to the first $100 of costs and
        expenses. The insurance program limits are $725 for costs and expenses
        in excess of the $100. The company has submitted, and will continue to
        submit, requests for payment to its insurance carriers for costs
        associated with this matter. This matter relates to the Agriculture
        segment.
        Second quarter 2012 included a charge of $(137) recorded in Cost of
(b)     goods sold and other operating charges primarily related to the
        company's settlement of litigation with Invista. This matter is
        included in Other.
        Second quarter 2012 included a pre-tax gain of $122 recorded in Other
(c)     income, net associated with the sale of an equity method investment in
        the Electronics & Communications segment.
        Second quarter 2011 included charges related to the Danisco
        acquisition of $(103) recorded in Cost of goods sold and other
        operating charges. These charges included $(60) of transaction costs
(d)     and a $(43) charge related to the fair value step-up of inventories
        that were acquired from Danisco and sold in the second quarter 2011.
        Pre-tax charges by segment were: Industrial Biosciences - $(17),
        Nutrition & Health - $(33), and Corporate expenses - $(53).
        Third quarter 2012 included a $(152) restructuring charge recorded in
        Employee separation/asset related charges, net consisting of $(133) of
        severance and related benefit costs and $(19) of asset related charges
        as a result of the company's plan to eliminate corporate costs
(e)     previously allocated to Performance Coatings and cost-cutting actions
        to improve competitiveness. Pre-tax charges by segment were:
        Agriculture - $(3), Nutrition & Health - $(13), Electronics &
        Communications - $(7), Performance Chemicals - $(3), Performance
        Materials - $(9), Safety & Protection - $(55), Industrial Biosciences
        - $(3), and Corporate expenses - $(59).
        Third quarter 2012 included a $(242) impairment charge recorded in
        Employee separation/asset related charges, net related to asset
        groupings within the Electronics & Communications and Performance
(f)     Materials segments. The charge of $(150) within Electronics &
        Communications was a result of conditions within the thin film
        photovoltaic market. The charge of $(92) within Performance Materials
        was the result of deteriorating conditions in an industrial polymer
        market.
        Third quarter 2011 included charges related to the Danisco acquisition
        of $(171). These charges included $(135) recorded in Cost of goods
        sold and other operating charges for $(3) of transaction costs and a
        $(132) charge related to the fair value step-up of inventories that
(g)     were acquired from Danisco and sold in the third quarter 2011. These
        charges also included a $(36) restructuring charge recorded in
        Employee separation / asset related charges, net related to severance
        and related benefit costs. Pre-tax charges by segment were:
        Industrial Biosciences - $(61), Nutrition & Health - $(89), Other -
        $(18), and Corporate expenses - $(3).
        Third quarter 2011 included a ($50) charge recorded in Research and
(h)     development expense in connection with a milestone payment associated
        with a Pioneer licensing agreement.
        Fourth quarter 2012 included a $(66) restructuring charge recorded in
        Employee separation/asset related charges, net primarily as a result
        of the company's plans to eliminate corporate costs previously
        allocated to Performance Coatings and cost-cutting actions to improve
        competitiveness, partially offset by a reversal of prior year
        restructuring accruals. Pre-tax charges by segment are: Agriculture -
        $(8), Electronics & Communications - $(2), Nutrition & Health - $(36),
(i)     Performance Materials - $(3), Safety & Protection - $(3), Other - $11,
        and Corporate expenses - $(25). Fourth quarter 2011 included a $(17)
        restructuring charge recorded in Employee separation/asset related
        charges, net primarily related to severance and related benefit costs
        associated with the Danisco acquisition, partially offset by a
        reversal of prior year restructuring accruals. Pre-tax charges by
        segment were: Industrial Biosciences - $(1), Nutrition & Health -
        $(4), Performance Materials - $(2), and Other - $(10).
        Fourth quarter 2012 included a $(33) impairment charge recorded in
        Employee separation/asset related charges, net related to an asset
(j)     group within the Performance Chemicals segment. The charge was a
        result of strategic decisions related to deteriorating conditions
        within a specific industrial chemicals market.
        Fourth quarter 2012 included a pre-tax gain of $117 recorded in Other
(k)     income, net associated with the sale of a business within the
        Agriculture segment.
        Fourth quarter 2011 included a pre-tax gain of $49 recorded in Other
(l)     income, net associated with the sale of a business in the Performance
        Materials segment and a related tax benefit of $73.
(m)     Earnings per share for the year may not equal the sum of quarterly
        earnings per share due to changes in average share calculations.
See Schedule C for detail by
segment.



E. I. du Pont de Nemours and Company

Consolidated Segment Information

(Dollars in millions)
SCHEDULE C
                                    Three Months Ended     Year Ended
                                    December 31,           December 31,
SEGMENT SALES ^(1)                  2012         2011      2012      2011
Agriculture                         $ 1,535      $ 1,297   $ 10,426  $  9,166
Electronics & Communications        622          630       2,701     3,173
Industrial Biosciences              300          289       1,180     705
Nutrition & Health                  853          806       3,422     2,460
Performance Chemicals               1,588        1,860     7,188     7,794
Performance Materials               1,534        1,618     6,447     6,815
Safety & Protection                 964          943       3,825     3,934
Other                               1            1         5         40
Total Segment sales                 7,397        7,444     35,194    34,087
Elimination of transfers            (72)         (101)     (382)     (406)
Consolidated net sales              $ 7,325      $ 7,343   $ 34,812  $ 33,681
(1) Sales for the reporting segments include transfers.



E. I. du Pont de Nemours and Company

Consolidated Segment Information

(Dollars in millions)
SCHEDULE C (continued)
                                        Three Months Ended  Year Ended
                                        December 31,        December 31,
PRE-TAX OPERATING INCOME/(LOSS) (PTOI)  2012      2011      2012      2011
FROM CONTINUING OPERATIONS
Agriculture                            $ (118)   $ (216)   $ 1,594   $ 1,527
Electronics & Communications            22        42        135       355
Industrial Biosciences                  44        33        168       (1)
Nutrition & Health                      30        48        299       44
Performance Chemicals                   167       433       1,586     1,923
Performance Materials                   251       198       1,013     971
Safety & Protection                     85        94        360       500
Pharmaceuticals                        9         89        62        289
Other                                   (60)      (84)      (385)     (263)
Total Segment PTOI                      430       637       4,832     5,345
Net exchange gains (losses) ^(1)        (54)      (14)      (215)     (146)
Corporate expenses & net interest       (392)     (320)     (1,502)   (1,418)
(Loss) income before income taxes from  $  (16)  $ 303    $ 3,115   $ 3,781
continuing operations
                                        Three Months Ended  Year Ended
                                        December 31,        December 31,
SIGNIFICANT ITEMS BY SEGMENT (PRE-TAX)  2012      2011      2012      2011
^(2)
Agriculture                            $  (26)  $ (100)   $ (469)  $ (225)
Electronics & Communications            (2)       -         (37)      -
Industrial Biosciences                  -         (1)       (3)       (79)
Nutrition & Health                      (36)      (4)       (49)      (126)
Performance Chemicals                   (33)      -         (36)      -
Performance Materials                   (3)       47        (104)     47
Safety & Protection                     (3)       -         (58)      -
Pharmaceuticals                        -         -         -         -
Other                                   11        (10)      (126)     (28)
Total significant items by segment      $  (92)  $  (68)  $ (882)  $ (411)
                                        Three Months Ended  Year Ended
                                        December 31,        December 31,
PTOI EXCLUDING SIGNIFICANT ITEMS        2012      2011      2012      2011
Agriculture                            $  (92)  $ (116)   $ 2,063   $ 1,752
Electronics & Communications            24        42        172       355
Industrial Biosciences                  44        34        171       78
Nutrition & Health                      66        52        348       170
Performance Chemicals                   200       433       1,622     1,923
Performance Materials                   254       151       1,117     924
Safety & Protection                     88        94        418       500
Pharmaceuticals                        9         89        62        289
Other                                   (71)      (74)      (259)     (235)
Total Segment PTOI excluding            $ 522    $ 705    $ 5,714   $ 5,756
significant items
(1) See Schedule D for additional information on exchange gains and losses.
(2) See Schedule B for detail of significant items.



E. I. du Pont de Nemours and Company

Reconciliation of Non-GAAP Measures

(Dollars in millions, except per share amounts)
SCHEDULE D
Summary of
Earnings
Comparisons
                          Three Months Ended                Year Ended
                          December 31,                     December 31,
                          2012         2011         %       2012         2011         %
                                                    Change                            Change
Segment PTOI              $       $       -32%    $        $        -10%
                           430        637                4,832       5,345
Significant items
(benefit) charge          92           68                   882          411
included in PTOI (per
Schedule C)
Segment PTOI excluding    $       $       -26%    $        $        -1%
significant items          522        705                5,714       5,756
Income from continuing    $       $               $        $    
operations after income     19       293        -94%    2,493       3,155       -21%
taxes
Significant items
(benefit) charge
included in income from
continuing operations
after income taxes        91           (47)                 680          237
(per Schedule B)
Income from continuing
operations after income   $       $       -55%    $        $        -6%
taxes, excluding           110        246                3,173       3,392
significant items
EPS from                  $       $               $       $     
continuing                 0.02       0.31        -94%    2.61        3.30        -21%
operations
Significant items
(benefit) charge          0.09         (0.05)               0.72         0.25
included in EPS (per
Schedule B)
EPS from continuing       $       $               $       $     
operations, excluding      0.11       0.26        -58%    3.33        3.55        -6%
significant items
Average number of
diluted shares            941,219,000  935,709,000  1%      942,197,000  941,029,000  0%
outstanding
Reconciliation of
Operating Earnings Per
Share (EPS) Outlook
The reconciliation below represents the company's outlook on an operating earnings basis,
defined as earnings from continuing operations excluding significant items and non-operating
pension/OPEB costs, as presented on December 13, 2012.
                          Year Ended December 31,
                          2013         2012 Actual
                          Outlook
Operating EPS             $3.85 -     $     
                          $4.05       3.77
Significant items
1Q 2013 U.S. tax
law items                 0.07         -
retroactive to
2012 - estimate
Sale of an equity                      0.08
method investment
Customer claims                        (0.39)
charges
Restructuring                          (0.17)
charge/adjustments
Litigation                             (0.13)
settlement
Asset impairment                       (0.19)
charge
Sale of business                       0.08
Non-operating
pension/OPEB costs        (0.42)       (0.47)
- estimate
Impact of LIFO            -            0.03
accounting change
Reported EPS from         $3.50 -     $     
continuing                $3.70       2.61
operations



E. I. du Pont de Nemours and Company

Reconciliation of Non-GAAP Measures

(Dollars in millions)
SCHEDULE D
Reconciliations of Adjusted EBIT / EBITDA to
Consolidated Income Statements
                                     Three Months Ended   Year Ended
                                     December 31,         December 31,
                                     2012       2011      2012       2011
(Loss) income from continuing
operations before income             $  (16)  $  303  $  3,115  $  3,781
taxes
Less: Net income attributable to     1          4         25         36
noncontrolling interests
Add: Interest expense              117        116       464        447
Adjusted EBIT from continuing        100        415       3,554      4,192
operations
Add: Depreciation and                394        393       1,631      1,451
amortization
Adjusted EBITDA from                 $  494   $  808  $  5,185  $  5,643
continuing operations
Calculation of Free Cash Flow -
Total Company
                                     Year Ended
                                     December 31,
                                     2012       2011
Cash provided by (used for)          $ 4,849    $ 5,152
operating activities
Less: Purchases of property,         1,793      1,843
plant and equipment
Free cash flow                       $ 3,056    $ 3,309



E. I. du Pont de Nemours and Company

Reconciliation of Non-GAAP Measures

(Dollars in millions)
SCHEDULE D (continued)
Exchange Gains/Losses
The company routinely uses forward exchange contracts to offset
its net exposures, by currency, related to the foreign currency
denominated monetary assets and liabilities of its operations.
The objective of this program is to maintain an approximately
balanced position in foreign currencies in order to minimize, on
an after-tax basis, the effects of exchange rate changes. The
net pre-tax exchange gains and losses are recorded in Other
income, net and the related tax impact is recorded in Provision
for (benefit from) income taxes on the Consolidated Income
Statements.
                                Three Months
                                Ended             Year Ended
                                                  December 31,
                                December 31,
                                2012      2011    2012    2011
Subsidiary/Affiliate
Monetary Position Gain
(Loss)
Pre-tax exchange gains          $      $     $     $  
(losses) (includes               (8)             (58)  
equity affiliates)                        (83)           (13)
Local tax benefits              9         4       19      35
(expenses)
Net after-tax impact            $      $     $     $  
from subsidiary exchange          1             (39)   
gains (losses)                            (79)           22
Hedging Program Gain
(Loss)
Pre-tax exchange gains          $      $     $     $  
(losses)                        (46)            (157)   (133)
                                          69
Tax benefits (expenses)         16        (24)    54      46
Net after-tax impact            $      $     $     $  
from hedging program            (30)            (103)   
exchange gains (losses)                   45             (87)
Total Exchange Gain
(Loss)
Pre-tax exchange gains          $      $     $     $  
(losses)                        (54)             (215)   (146)
                                          (14)
Tax benefits (expenses)         25        (20)    73      81
Net after-tax exchange          $      $     $     $  
gains (losses) ^(1)             (29)             (142)   
                                          (34)           (65)
As shown above, the "Total Exchange Gain (Loss)" is the sum of
the "Subsidiary/Affiliate Monetary Position Gain (Loss)" and the
"Hedging Program Gain (Loss)."
(1) The above Net after-tax exchange gains (losses) excludes
gains (losses) attributable to discontinued operations of $(3)
and $(5) for the three months ended December 31, 2012 and 2011,
respectively, and $(14) and $(17) for the year ended December
31, 2012 and 2011, respectively.
Reconciliation of Base Income Tax Rate to
Effective Income Tax Rate
Base income tax rate is defined as the effective income tax rate
less the effect of exchange gains/losses, as defined above, and
significant items.
                                Three Months
                                Ended             Year Ended
                                                  December 31,
                                December 31,
                                2012      2011    2012    2011
(Loss) income from              $      $     $      $  
continuing operations           (16)       303  3,115  3,781
before income taxes
Add: Significant items         117       68      966     467
- (benefit) charge ^(2)
Less: Net exchange             (54)      (14)    (215)   (146)
(losses) gains
Income from continuing
operations before income
taxes, significant items and
exchange
gains/losses                    $      $     $      $  
                                155        385  4,296  4,394
(Benefit from) provision        $      $     $     $  
for income taxes on             (35)             622    626
continuing operations                     10
Add: Tax benefit
(expenses) on                   26        115     286     230
significant items
 Tax benefits
(expenses) on exchange          25        (20)    73      81
gains/losses
Provision for income taxes on
continuing operations,
excluding taxes on significant  $      $     $     $  
items                            16       105   981    937
 and exchange
gains/losses
Effective income tax            218.8%    3.3%    20.0%   16.6%
rate
Significant items effect        (227.7%)  30.4%   2.2%    3.6%
Tax rate, from
continuing operations,          (8.9%)    33.7%   22.2%   20.2%
before significant items
Exchange gains (losses)         19.2%     (6.4%)  0.6%    1.1%
effect
Base income tax rate
from continuing                 10.3%     27.3%   22.8%   21.3%
operations
(2) See Schedule B for
detail of significant
items.



E. I. du Pont de Nemours and Company

Consolidated Segment Information

(Dollars in millions)
SCHEDULE E
Below represents the company's estimated 4Q and Full Year 2012 segment
operating earnings reflecting the change in reporting for the cost of
non-operating pension and other post-employment benefits and excluding
significant items.
                                       Three Months        Year Ended
                                       Ended               December 31,
                                       December 31,
SEGMENT OPERATING EARNINGS             2012                2012
Agriculture                           $           $     
                                             (78)    2,138
Electronics & Communications           43                  259
Industrial Biosciences                 42                  162
Nutrition & Health                     58                  326
Performance Chemicals                  237                 1,814
Performance Materials                  273                 1,225
Safety & Protection                    133                 620
Pharmaceuticals                       9                   62
Other                                  (101)               (355)
Total Segment Operating Earnings       616                 6,251
Significant items benefit              (92)                (882)
(charge)^(1)
Non-operating pension/OPEB costs       (144)               (615)
LIFO/Other reporting changes           50                  78
Total Segment PTOI                     $           $     
                                             430     4,832
(1) See Schedule B for detail of significant items.





SOURCE DuPont

Website: http://www.dupont.com
Contact: Media Contact: Michael Hanretta, +1-302-774-4005,
michael.j.hanretta@usa.dupont.com; Investor Contact: +1-302-774-4994
 
Press spacebar to pause and continue. Press esc to stop.